Kazia Therapeutics (KZIA) News Today → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free KZIA Stock Alerts $0.36 -0.02 (-5.20%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineKazia Therapeutics Limited (NASDAQ:KZIA) Sees Significant Increase in Short Interestamericanbankingnews.com - April 16 at 1:26 AMKazia Therapeutics Ltd ADR KZIAmorningstar.com - March 20 at 4:52 PMKZIA Apr 2024 2.500 callfinance.yahoo.com - March 16 at 12:37 AMKazia announces presentation of new data at AACR Annual Meetingprnewswire.com - March 13 at 8:00 AMWhat's Going With Australia-Based Cancer Firm Kazia Therapeutics On Wednesday?msn.com - February 21 at 6:59 PMKazia Therapeutics Limited: Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpointfinanznachrichten.de - February 21 at 1:58 PMKazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpointfinance.yahoo.com - February 21 at 8:58 AMKazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpointprnewswire.com - February 21 at 7:30 AMKazia Therapeutics Limitedthestreet.com - February 19 at 6:40 PMKazia Therapeutics Ltd. ADRwsj.com - February 14 at 7:28 PMViking Therapeutics, Inc. Common Stock (VKTX)nasdaq.com - February 13 at 3:25 AMKAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTSfinance.yahoo.com - January 18 at 9:40 AMKazia Therapeutics files to sell 591,697 ADSs for holdersmsn.com - December 15 at 10:44 PMKazia Therapeutics Announces Closing of $2 Million Registered Direct Offeringfinance.yahoo.com - December 5 at 11:06 PMKazia Therapeutics Shares Tumble on $2 Million Direct Offeringmarketwatch.com - December 1 at 9:29 AMKazia Therapeutics Announces Registered Direct Offering - Quick Factsmarkets.businessinsider.com - December 1 at 9:29 AMKazia Therapeutics Announces $2 Million Registered Direct Offeringfinance.yahoo.com - December 1 at 9:29 AMKazia Therapeutics Enters Non-binding LOI For Paxalisib Rights Outside Of Oncologymarkets.businessinsider.com - November 29 at 1:55 PMKazia stock jumps after proposed license deal for paxalisib outside oncologymsn.com - November 29 at 1:55 PMKazia Therapeutics Signs Letter of Intent for Paxalisib Development, Commercializationmarketwatch.com - November 29 at 7:53 AMKAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGYfinance.yahoo.com - November 29 at 7:53 AMKAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETINGfinance.yahoo.com - November 21 at 8:56 AMKazia Therapeutics gets deficiency notice from Nasdaqmsn.com - November 20 at 7:08 PMKazia Therapeutics Limited's (NASDAQ:KZIA) large institutional owners must be happy as stock continues to impress, up 28% over the past weekfinance.yahoo.com - November 18 at 11:59 AMKAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETINGfinance.yahoo.com - November 15 at 12:07 PMKazia Provides Preliminary Update From Phase 2 Study Of Paxalisib In Primary CNS Lymphoma; Stock Upmarkets.businessinsider.com - November 1 at 9:18 AMKazia issues update on paxalisib study in CNS lymphoma patientsmsn.com - November 1 at 9:18 AMKAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMAfinance.yahoo.com - November 1 at 9:18 AMKAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDYfinance.yahoo.com - October 23 at 10:02 AMmarketbeat.com - October 6 at 6:01 AMKazia Therapeutics Limited - ADR (KZIA) Price Target Increased by 7.17% to 1.08msn.com - October 5 at 5:37 PMKAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGSfinance.yahoo.com - October 5 at 7:36 AMKAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETINGfinance.yahoo.com - September 29 at 9:51 AMKazia Therapeutics Limited - ADR (KZIA) Price Target Decreased by 12.12% to 1.15msn.com - August 3 at 7:26 PMTraders Digest Strong Jobs Data, Fed Minutes, Fueling Premarket Losses for US Equity Futuresmsn.com - July 7 at 7:33 AMWhat's Going On With Kazia Therapeutics Stock Today?msn.com - July 6 at 3:21 PMKazia Therapeutics Shares Higher Premarket on Key FDA Designation >KZIAmarketwatch.com - July 6 at 10:21 AMKazia jumps as FDA awards Fast Track tag for lead programmsn.com - July 6 at 10:21 AMKAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPYfinance.yahoo.com - July 6 at 10:21 AMInsider Stock Buying Reaches AU$1.1m On Kazia Therapeuticsfinance.yahoo.com - July 4 at 7:30 PMKAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMAfinance.yahoo.com - June 8 at 10:41 AMKAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOTfinance.yahoo.com - May 25 at 11:24 AMKazia Therapeutics appoints Dr John Friend as new CEOproactiveinvestors.com - May 1 at 12:10 AMKAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENTfinance.yahoo.com - April 14 at 8:57 AMKAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETINGfinance.yahoo.com - April 4 at 7:58 AMKazia Therapeutics to present new pipeline molecule data at AACR 2023proactiveinvestors.com - April 3 at 8:57 PMKazia Therapeutics forms clinical collaboration for Australian Phase 2 study of paxalisib, targeting childhood cancersproactiveinvestors.com - March 6 at 7:18 PMKazia Therapeutics raises A$7 million to fund R&D pipelineproactiveinvestors.com - February 27 at 9:16 PMKZIA Kazia Therapeutics Limitedseekingalpha.com - February 22 at 5:12 PMKazia Therapeutics Stock (NASDAQ:KZIA), Quotes and News Summarybenzinga.com - February 18 at 3:22 PM Get Kazia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter. Email Address “Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers. Find out why right here (and see what you can do to get in too with just a few dollars). KZIA Media Mentions By Week KZIA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KZIA News Sentiment▼1.000.37▲Average Medical News Sentiment KZIA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KZIA Articles This Week▼10▲KZIA Articles Average Week Get Kazia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ENSC News PTPI News ARTL News PXMD News SNGX News LIPO News DRUG News SNPX News LMDX News GNPX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KZIA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kazia Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
